Table 2.
Clinical characteristics of the study population, for each variable the percentages are calculated per stage
| Patients (n = 72) | Carers (n = 17)c | ||||
|---|---|---|---|---|---|
| Stage I (n = 18) | Stage II (n = 10)a | Stage III (n = 16)b | Stage IV (n = 28) | ||
| Melanoma diagnosis: | |||||
| < 1 month ago | – | – | – | – | – |
| 1–3 months ago | 6% | – | – | – | – |
| 3–6 months ago | 17% | – | 7% | 4% | – |
| 6–12 months ago | 28% | 10% | 13% | 11% | 6% |
| 1–2 years ago | 6% | 20% | 7% | 25% | 29% |
| 2–5 years ago | 22% | 50% | 40% | 43% | 24% |
| > 5 years ago | 22% | 20% | 33% | 18% | 41% |
| Type of Melanoma:d | |||||
| Cutaneous melanoma | 44% | 70% | 57% | 64% | 62% |
| Ocular/ Uveal/Choroidal melanoma | 50% | 10% | 7% | 18% | 12% |
| Acral melanoma | – | – | – | – | 6% |
| Mucosal melanoma | – | – | – | – | – |
| I don’t know | 6% | 20% | 36% | 18% | 19% |
| Melanoma mutations: | |||||
| BRAF mutant | 11% | 20% | 27% | 46% | 53% |
| BRAF wild-type | – | – | – | 18% | 18% |
| NRAS mutant | – | – | – | 7% | – |
| c-kit mutant | – | – | – | 4% | 6% |
| GNAQ/GNA11 | – | – | 7% | 4% | – |
| I don’t know | 78% | 60% | 67% | 11% | 18% |
| None | 6% | 10% | – | 4% | 6% |
| Othere | 6% | 10% | – | 7% | – |
| Treatments receivedf | |||||
| Surgery | 89% | 90% | 94% | 89% | 100% |
| Radiotherapy | 39% | 20% | 13% | 39% | 26% |
| Chemotherapy | – | 11% | 6% | 25% | 21% |
| Immune Therapies | – | – | 25% | 81% | 56% |
| Targeted Therapies | – | – | 6% | 27% | 50% |
aThe total number of respondents on treatments received (chemotherapy) was 9; bThe total number of respondents on melanoma diagnosis is 15, on type of melanoma is 14, melanoma mutation is 15, and on treatments received is 15; cCarers provided disease specific characteristics for the patient they care(d) for; dThe total number of respondents on type of melanoma is 16, on treatments received is 16; − no respondents ticked this answer (e.g. 0%); eOther melanoma mutations mentioned by 4 respondents were mutations in chromosome 3, 6 and/or 8; fthe percentage for ‘treatments received’ could be more than 100% because patients may have received more than one treatment; NA: Not Applicable